A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement

Leuk Lymphoma. 2022 Apr;63(4):1013-1015. doi: 10.1080/10428194.2021.2005043. Epub 2021 Dec 2.

Authors

Yukiko Doi¹, Takafumi Yokota¹, Hirohiko Shibayama¹, Kana Matsumoto², Masako Kurashige³, Kenji Nozaki¹, Jiro Fujita¹, Kentaro Fukushima¹, Naoki Hosen¹

Affiliations

¹ Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
² Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
³ Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

PMID: 34852707
DOI: 10.1080/10428194.2021.2005043

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Central Nervous System
Humans
Lymphoma, T-Cell, Peripheral* / drug therapy
Purine Nucleosides* / therapeutic use
Pyrimidinones / therapeutic use

Substances

Purine Nucleosides
Pyrimidinones
forodesine